Monitoring serum bactericidal activity determination in patients with renal insufficiency undergoing antibacterials

doi:10.3969/j.issn.1673-8640.2014.11.013

Abstract

Abstract:

Objective　To monitor serum bactericidal activity（SBA） determination in renal insufficiency patients during antibiotics treatment， to adjust the antibiotics dosage and dosing interval， to formulate individualized dosing regimen， and to improve the treatment and decrease the side effects. Methods　A total of 48 renal insufficiency [glomerular filtration rate（GFR）＜50 mL/min] patients undergoing cephalosporin treatment were enrolled， including 36 cases with middle renal insufficiency and 12 cases with severe renal insufficiency， their antibiotics dosage and dosing interval were adjusted according to the guideline of antibiotics treatment for renal insufficiency patients， and the peak and valley SBA values were measured by the method we designed. Results　In 36 patients with middle renal insufficiency， the peak SBA value was 1∶32-1∶128（median 1∶64）， and the valley SBA value was 1∶8-1∶64（median 1∶32）. In 12 patients with severe renal insufficiency， the peak SBA value was 1∶64-1∶512（median 1∶128）， and the valley SBA value was 1∶16-1∶128（median 1∶64）. The SBA values in the 2 groups were all higher than reasonable suggestion value（P＜0.01）. Conclusions　In patients with renal insufficiency undergoing antibiotics treatment mainly metabolized by kidney， there will increase the side effects and renal insufficiency. It should monitor SBA value， when using antibiotics mainly metabolized by kidney in patients with renal insufficiency.

Key words: Serum bactericidal activity, Renal insufficiency, Antibacterials, Individualized dosing

CLC Number:

R446.5

DONG Chenglin, XU Ling, SHAO Yan, CUI Bangquan, LIU Zhihui, HONG Huifeng. Monitoring serum bactericidal activity determination in patients with renal insufficiency undergoing antibacterials[J]. , 2014, 29(11): 1132-1135.

References

[1] Wolfson JS,Swartz MN.Drug therapy. Serum bactericidal activity as a monitor of antibiotic therapy[J].New Engl J Med,1985,312(15) :968-973.
[2] 王睿.临床抗感染药物治疗学[M].北京:人民卫生出版社,2006:162-163.
[3] 崔邦铨,周宗.微量血清杀菌活性测定的临床应用[J].中国冶金工业医学杂志,2002,19(1):60.
[4] 洪慧丰,李安华.微量法测定血清杀菌效价的临床应用[J].中国药师,2003,6(8):483-485.
[5] 文爱东.抗菌药物规范化及个体化应用指南[M].北京:人民军医出版社,2012:194.
[6] 叶应妩,王毓三,申子瑜,等.全国临床检验操作规程[M].第3版.南京:东南大学出版社,2006:897.
[7] Hyatt JM,Nix DE,Schentag JJ.Pharmacokinetic and pharmacodynamic activities of ciprofloxacin against strains of Streptococcus pneumoniae , Staphylococcus aureus , and Pseudomonas aeruginosa for which MICs are similar[J]. Antimicrob Agents Chemother, 1994,38(12):2730-2737.
[8] National Committee for Clinical Laboratory Standards. Methods for determining bactericidal activity of antimicrobial agents[S]. M21-A, NCCLS, 1999.
[9] Shaw JP, Seroogy J, Kaniga K, et al.Pharmacokinetics, serum inhibitory and bactericidal activity, and safety of telavancin in healthy subjects[J].Antimicrobial Agents Chemother, 2005,49(1):195-201.
[10] Hart D, Weinstein MP.Cross-over assessment of serum bactericidal activity of moxifloxacin and levofloxacin versus penicillin-susceptible and penicillin-resistant Streptococcus pneumoniae in healthy volunteers[J]. Diagn Microbiol Infect Dis,2007,58(3):375-378.
[11] 杨延停,陈汝贤,许鸿章,等.Sansanmycin A对铜绿假单胞菌体内外抗菌活性的初步研究[J].中国抗生素杂志,2012,37(3):196-201.
[12] 白艳,王瑾,蔡芸,等.头孢噻利不同剂量单次静滴在中国健康人群的血清杀菌活性[J].中国临床药理学杂志,2013,29(3):192-195.
[13] 伏晓,代大顺,焦伟杰.应用抗菌药物继发真菌感染临床分析[J].中华医院感染学杂志,2013,23(14):3501-3503.
[14] 汪复,张婴元.抗菌药物临床应用指南[M].第2版.北京:人民卫生出版社,2012:38-54.
[15] 周家军,董盈盈,梁蓓蓓,等.抗菌药物血清杀菌活性研究的临床意义[J].中国临床药理学杂志,2010,26(11):877-880.
[16] 白艳,王瑾,梁蓓蓓,等.头孢拉宗钠不同剂量单次静滴后在健康人血清的杀菌活性[J].中国临床药理学杂志,2011,27(11):822-826.